Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859211 | 0.84 | MAPT (0.42) | MAPTCYP2A6PTGS1GRM5CYP2E1 | |
| SCHEMBL4875437 | 0.84 | MAPT (0.47) | MAPTCYP2A6PTGS1GRM5CYP2E1 | |
| SCHEMBL4869156 | 0.84 | MAPT (0.36) | MAPTCYP2A6PTGS1GRM5CYP2E1 | |
| SCHEMBL4808663 | 0.78 | CYP2A6 (0.54) | MAPTCYP2A6GRM5CYP2E1CYP3A4 | |
| SCHEMBL4875319 | 0.77 | MAPT (0.38) | MAPTCYP2A6PTGS1GRM5CYP2E1 | |
| SCHEMBL4805769 | 0.77 | MAPT (0.39) | MAPTCYP2A6PTGS1PTGS2FLT3 | |
| SCHEMBL4875800 | 0.77 | IRAK4 (0.43) | MAPTCYP2A6PTGS1CYP11B2 | |
| SCHEMBL4810066 | 0.77 | CYP2A6 (0.45) | MAPTCYP2A6PTGS1GRM5CYP2E1 | |
| SCHEMBL4809561 | 0.76 | CYP3A4 (0.52) | CYP2A6CYP3A4CYP11B2 | |
| SCHEMBL4878280 | 0.76 | CYP2A6 (0.40) | MAPTCYP2A6PTGS1GRM5CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | claimed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | MAPT 964/4885CYP2A6 157/4885PTGS1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.